C
Century Kangtai / 世纪康泰
Advanced ophthalmic medical devices and collagen biomaterials
About Century Kangtai / 世纪康泰
Founded in 2008 by Pei Xiujuan, Tianjin Century Kangtai Biomedical Engineering Co., Ltd. is a high-end medical device company integrating research and development, production, and sales. The company is headquartered in the Tianjin Development Zone and operates GMP-compliant facilities, including a 10,000-level clean production workshop.
The firm's business is centered on two primary segments: innovative ophthalmic solutions and collagen-based biomaterials. Its ophthalmology portfolio includes a wide range of intraocular lenses (IOLs), such as hydrophilic and hydrophobic, aspheric, toric, and multifocal models. Notably, the company has developed unique domestic designs like the edge-enhanced zero spherical aberration and hollow-loop IOLs, catering to patients with specific comorbidities. The product line also extends to optometry products like rigid gas permeable (RGP) lenses and defocus lenses. In the biomaterials sector, Tianjin Century Kangtai produces collagen sponges for surgical applications and a line of collagen-based products for medical aesthetics and functional skincare. The company is one of the few in China that possesses the technology for implant-grade collagen raw materials.
The company's business model involves the direct sale of its products, supported by a wholly-owned subsidiary, Century Kangtai (Tianjin) Technology Development Co., Ltd., which manages nationwide sales and service. After securing A-round financing in 2022, the company has expanded its production capabilities with a second industrialization project. Tianjin Century Kangtai holds numerous patents and has received multiple Class II and Class III medical device registration certificates from China's National Medical Products Administration, as well as CE certification for its IOLs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2023 | $28M | $110M | SDIC Unity Capital · Jinju Capital · Songshan Lake Venture Capital · Efung Capital | ↗ |
| SERIES AEquity / VC | May 2022 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Century Kangtai / 世纪康泰 is 280 monthly website visits, down 76.7% over the last three months. Century Kangtai / 世纪康泰's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Century Kangtai / 世纪康泰 in its local ecosystem
The Century Kangtai / 世纪康泰 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
SDIC Unity Capital- JCJinju Capital
- SCSongshan Lake Venture Capital
- ECEfung Capital
- XCXiaochi Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Century Kangtai / 世纪康泰 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Century Kangtai / 世纪康泰’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








